Clinical Trial Update: Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL [Phase 2]

View source ↗

Summary

A Phase 2 trial of bendamustine, ofatumumab and methylprednisolone for relapsed B-cell chronic lymphocytic leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• METHYLPREDNISOLONE (methylprednisolone)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: B-cell Chronic Lymphocytic Leukemia (B-CLL) | Phase 2 | Status: TERMINATED